Age-related Macular Degeneration Market by Treatment Type (Anti-VEGF Therapy, Photodynamic Therapy, Laser Therapy, Nutritional Therapy), Diagnosis Type (Ophthalmoscopy, Fluorescein Angiography), and End-User (Hospitals, Ambulatory Surgical Centers); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Age-related Macular Degeneration Market was valued at USD 8.4 billion in 2023 and will surpass USD 15.3 billion by 2030; growing at a CAGR of 8.9% during 2024 - 2030.

The Age-Related Macular Degeneration (AMD) Market is a rapidly evolving sector within the global ophthalmology industry, driven by the increasing prevalence of AMD among the aging population. AMD is one of the leading causes of vision loss in individuals over the age of 50, making it a significant concern for both patients and healthcare providers. The market is characterized by a wide range of treatment options, from drug therapies to surgical interventions, aimed at slowing disease progression and improving quality of life for patients. As the global population continues to age, the demand for effective diagnostic and therapeutic solutions for AMD is expected to rise substantially. Advances in imaging technologies, as well as the development of more targeted therapies, are poised to drive market growth.

With a growing emphasis on early detection and personalized treatment approaches, the AMD market has witnessed notable developments in both the clinical and technological spheres. Leading pharmaceutical companies are focusing on innovations in drug therapies, particularly in anti-VEGF (vascular endothelial growth factor) treatment, which has revolutionized the management of AMD. Additionally, the increasing adoption of advanced diagnostic tools, such as fluorescein angiography, is enabling healthcare providers to detect the disease at earlier stages, thereby enhancing patient outcomes. As the demand for effective solutions continues to grow, the AMD market is likely to see rapid advancements and competitive dynamics.

Anti-VEGF Therapy Segment Is Largest Owing to Its Efficacy in Treating AMD

The Anti-VEGF Therapy segment is the largest in the Treatment Type category for Age-Related Macular Degeneration. Anti-VEGF drugs, such as Lucentis (ranibizumab), Eylea (aflibercept), and Avastin (bevacizumab), have revolutionized the treatment of wet AMD by inhibiting the growth of abnormal blood vessels in the retina, which is the hallmark of the condition. These therapies have shown significant efficacy in slowing disease progression and improving vision in patients with wet AMD, making them the treatment of choice for many healthcare providers.

The popularity of anti-VEGF therapy is attributed to its ability to provide long-term disease control with relatively minimal side effects, compared to other treatment modalities. Moreover, advancements in drug delivery mechanisms, such as intravitreal injections, have made anti-VEGF therapy more accessible and effective. The increasing adoption of these therapies in both developed and emerging markets is driving the dominance of this segment in the overall AMD market. With ongoing research into improved formulations and the potential for combination therapies, the anti-VEGF therapy segment is expected to maintain its leadership position in the AMD treatment landscape.

Fluorescein Angiography Segment Is Fastest Growing Owing to Advancements in Diagnostic Accuracy

In the Diagnosis Type category, Fluorescein Angiography is the fastest growing subsegment. This diagnostic procedure is crucial for detecting and assessing the extent of neovascularization (abnormal blood vessel growth) in the retina, which is a defining feature of wet AMD. The growing adoption of fluorescein angiography is driven by advancements in imaging technology, such as high-resolution digital cameras and real-time imaging techniques, which provide more accurate and detailed images of the retina. This allows ophthalmologists to diagnose AMD at earlier stages, improving patient outcomes through timely intervention.

Fluorescein angiography remains a critical tool for not only diagnosing AMD but also monitoring the progression of the disease and evaluating the effectiveness of treatments. Its increasing use in combination with optical coherence tomography (OCT) has enhanced the precision of AMD diagnosis, contributing to the growing popularity of this diagnostic method. With the increasing availability of advanced diagnostic equipment and improved imaging resolution, the fluorescein angiography segment is expected to continue growing rapidly, particularly in developed regions with high healthcare spending.

Hospitals Segment Is Largest End-Use Industry Owing to Comprehensive Treatment Capabilities

The Hospitals segment is the largest end-user category in the Age-Related Macular Degeneration market. Hospitals offer a comprehensive range of services, including diagnostic testing, treatment, and patient management, making them the primary healthcare setting for AMD care. The availability of specialized ophthalmology departments, advanced diagnostic equipment, and access to skilled healthcare professionals contributes to the dominance of hospitals in this market segment.

Hospitals also benefit from their capacity to administer more complex treatments, such as intravitreal injections for anti-VEGF therapy, which require a controlled medical environment. Additionally, the growing trend of integrated care, where multidisciplinary teams collaborate to provide comprehensive care, further strengthens hospitals' position as the leading end-use sector for AMD treatments. The continued development of specialized AMD treatment centers within hospitals is expected to sustain this segment's market dominance.

North America Leads the Market Owing to High Healthcare Spending and Advanced Diagnostic Infrastructure

North America is the largest region in the Age-Related Macular Degeneration Market, driven by high healthcare expenditure, advanced diagnostic capabilities, and widespread access to cutting-edge treatments. The United States, in particular, has seen substantial growth in the adoption of anti-VEGF therapies and diagnostic technologies, making it a key market for AMD treatment and diagnosis. The aging population in North America is a significant driver of this demand, as a higher proportion of elderly individuals are at risk for developing AMD.

The region also benefits from the presence of leading pharmaceutical companies and a highly developed healthcare infrastructure, which ensures rapid adoption of new treatments and diagnostic tools. Furthermore, North American patients have greater access to insurance coverage for treatments, enabling a broader demographic to seek medical care. As a result, North America is expected to maintain its leadership in the global AMD market.

Competitive Landscape: Leading Companies and Market Dynamics

The Age-Related Macular Degeneration Market is highly competitive, with several leading companies driving innovation in both treatment and diagnostic solutions. Key players in the treatment segment include Regeneron Pharmaceuticals, Novartis, Roche, and Bayer, which dominate the market with their anti-VEGF therapies. These companies are at the forefront of clinical research, aiming to develop more effective and long-lasting treatments for AMD. Additionally, advancements in gene therapy and combination treatments are being explored by these industry leaders to further address unmet needs in AMD care.

In the diagnostic segment, companies such as Zeiss, Topcon Corporation, and Canon Medical Systems lead the market with their advanced imaging technologies, including fluorescein angiography and OCT devices. These companies are continually enhancing their diagnostic systems to provide more accurate, non-invasive, and faster results, contributing to better patient management. The competitive landscape is marked by continuous innovation, strategic partnerships, and mergers and acquisitions, as companies seek to expand their product portfolios and market presence in the rapidly evolving AMD market.

Recent Developments:

• Regeneron Pharmaceuticals announced a collaboration with a biotech company to enhance the development of new therapies for AMD.
• Novartis received FDA approval for a new anti-VEGF treatment for wet AMD.
• Bayer expanded its ophthalmology portfolio with the acquisition of an innovative retinal disease treatment.
• Roche launched a phase 3 clinical trial for a combination therapy targeting both dry and wet AMD.
• AbbVie secured regulatory approval for a new injection therapy for AMD, offering a longer-lasting treatment option.

List of Leading Companies:

• AbbVie
• Allergan (AbbVie)
• Apellis Pharmaceuticals
• Bayer
• Biogen
• Genentech (Roche)
• Kodiak Sciences
• Neovasc
• Novartis
• Ocular Therapeutix
• Regeneron Pharmaceuticals
• Roche
• Senju Pharmaceutical
• Spark Therapeutics
• ThromboGenics

Report Scope: